At the news
? BULLISHIMPACT 6/10 8-K filed Aug 5, 2026 at 07:10 ET
Kymera Therapeutics reported Q2 2026 collaboration revenue of $65.0M (well above $32.8M consensus) and EPS of -$0.62 (beating -$0.74 consensus). The key catalyst is the completion of enrollment in the KT-621 Phase 2b AD trial nearly six months ahead of schedule, pulling forward topline data to year-end 2026, along with $65M in milestone payments from Gilead and Sanofi. The company ended the quarter with $1.5B cash, providing runway into 2029.
- Collaboration revenue $65.0M vs consensus $32.8M (beat), driven by $45M Gilead option and $20M Sanofi milestone
- EPS -$0.62 vs consensus -$0.74 (16.0% beat)
- KT-621 BROADEN2 Phase 2b AD trial enrollment completed ~6 months ahead of schedule; data readout accelerated to year-end 2026
- KT-621 Phase 3 trials in AD planned to initiate by mid-2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access